Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome Combination Therapy in Advanced Solid Tumors
NCT05344742Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in solid tumor (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose Limiting Toxicity at 21 days and Treatment-Emergent Adverse Events. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05344742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344742.